Trial Pharma Kft.

Bekescsaba 19 trials 9 recruiting

19 Registered trials

9 Currently recruiting

Organisation

Trial Pharma Kft.

Location

Bekescsaba, Hungary

Identifier

ORG-100044848

Address

Zsigmond Ter 10, 1023, Hungary

Departments

-
Endocrinology
N/A
NA
Not applicable
Private practice
Trial Pharma Kft.

Clinical trials at this site (19)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting

2023-509124-18-00 Moderate-to-Severe Atopic Dermatitis 5 2025-12-19
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting

2023-509121-51-00 Moderate-to-Severe Atopic Dermatitis 5 2025-09-30
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease Recruiting

2024-516020-33-00 Grave’s Disease 4 2025-06-26
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and… Ended

2024-510626-89-00 Non-Alcoholic Steatohepatitis (NASH) 5 2019-11-18
A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended

2022-501884-41-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-29
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-20
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Moderate to severe atopic dermatitis 5 2018-10-10